Related Experiment Video
Updated: Apr 16, 2026
07:56
Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats
Published on: April 21, 2017
11.2K
Is migraine a risk factor for pediatric stroke?
Amy A Gelfand1, Heather J Fullerton2, Alice Jacobson3
1UCSF Headache Center, Department of Neurology, University of California San Francisco, USA Division of Child Neurology, UCSF, USA GelfandA@neuropeds.ucsf.edu.
Cephalalgia : an International Journal of Headache
|March 11, 2015
Summary
Pediatric migraineurs did not show a significant increase in stroke risk. However, adolescents with migraine experienced a higher risk of ischemic stroke, warranting further investigation into risk factors.
Area of Science:
- Neurology
- Pediatrics
- Epidemiology
Background:
- Childhood stroke risk factors remain incompletely understood.
- Migraine with aura is a known risk factor for ischemic stroke in adults.
Purpose of the Study:
- To investigate the association between migraine and stroke in children.
- To determine if migraine increases stroke risk in pediatric populations.
Main Methods:
- A cohort study was conducted using data from Kaiser Permanente Northern California (KPNC) from 1997-2007.
- Included were children aged 2-17 years with diagnosed migraine or no headache history.
- Stroke incidence rates and incidence rate ratios were calculated.
Main Results:
- No statistically significant increase in hemorrhagic or ischemic stroke was observed in pediatric migraineurs overall.
- A post-hoc analysis revealed a significantly elevated risk of ischemic stroke in adolescents (12-17 years) with migraine (IR 3.4).
- Hemorrhagic stroke incidence was lower in migraineurs compared to controls.
Conclusions:
- Migraine is not associated with a significant increase in overall stroke risk in children.
- Adolescents with migraine may have an elevated risk for ischemic stroke.
- Future research should explore risk factors for ischemic stroke in adolescent migraineurs, including migraine aura.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
507
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
507
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
362
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
362
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
391
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
01:30Attention-Deficit/Hyperactivity Disorder
1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
01:24Drug Toxicity: Risk factors
213
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
213
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
863
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
863